Loading…
← CockpitCompetitor Analysis › 002432.SZ Andon Health Co., Ltd. Class AOpen in the cockpit ↗

Andon Health Co., Ltd. Class A002432.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese home health-device maker selling glucose meters, blood pressure monitors and (via iHealth) COVID test kits.

≈ China's answer to a home-diagnostics brand like LifeScan/iHealthMomentum strong 62
Mkt cap
$3.86B
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$170M
20-day average traded
Fwd P/E
16.1×
forward earnings
ROIC−WACC
-5.7 pp
WACC 5.0%
Hurdle
+1 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥56.90
1D+5.2%
1W-4.4%
1M+7.1%
3M-21.4%
6M-23.5%
YTD+42.1%
1Y+43.0%
ATR %5.2%
52w lowhigh40.1% off high

What Andon Health does

Chinese home health-device maker selling glucose meters, blood pressure monitors and (via iHealth) COVID test kits.

Makes devices both for other brands and under its own iHealth label, selling to pharmacies, retailers and distributors. COVID test kits, including large US government test-distribution orders in 2021 and 2022, lifted it sharply and that demand has since faded, leaving blood pressure and glucose monitors as the steadier base.

In one line: China's answer to a home-diagnostics brand like LifeScan/iHealth.

Products and services

  • Blood glucose meters
  • Blood pressure monitors
  • Thermometers
  • Rapid antigen test kits (iHealth)

Customers

  • Retail pharmacies
  • Consumers
  • US distributors (iHealth)

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Home health monitoring & diagnostics

What could go right

  • Home health monitoring adoption
  • US retail distribution via iHealth

What could go wrong

  • COVID test demand normalization
  • Consumer product price competition

Moat: narrow (brand, distribution). iHealth brand and US retail/distribution ties built during COVID give consumer reach.

Headquarters: Tianjin, China · Employees: 1,249

Named competitors

Andon Health at a glance

Size Andon Health (002432.SZ) is a China Health Care company (Medical Specialties) with a market value of $3.86B, the 624th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥56.90 on 18 Nov 2026.

Performance Over six months the shares fell 23.5%, against +11.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 29.8% over the last twelve months (peer median +7.4%); the operating margin is -26.0% (peer median 12.6%).

Valuation It trades at 16.1× forward earnings against a peer median of 22.8× (4th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.7 points below its cost of capital (5.0% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 112002432.SZ 77
Six months, rebased to 100: Andon Health against the median of its 20 peers (local-currency closes).

Andon Health financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.10BCN¥1.36BCN¥2.59BCN¥3.19BCN¥26.3B
Revenue growth—-47%-19%-88%—
Gross profitCN¥714MCN¥827MCN¥1.78BCN¥1.95BCN¥20.9B
EBITDAn/a-CN¥246MCN¥743MCN¥857MCN¥18.6B
Net incomeCN¥5.88BCN¥2.27BCN¥1.67BCN¥1.25BCN¥16.0B
Free cash flowCN¥1.97BCN¥670MCN¥1.51BCN¥1.80BCN¥18.1B
Capital expenditureCN¥137MCN¥264MCN¥73.9MCN¥213MCN¥212M
Total debtCN¥9.15BCN¥5.68BCN¥3.36BCN¥1.58BCN¥318M

Quarterly statements and history in the cockpit →

Andon Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%CDNANVSTFIE1SXP603014TECN002223STVN4203AMBU-BAXGNPLSE603658TMDXICUI688301603301GRALSHC300003002432.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Andon Health is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%25×50×75×CDNANVSTFIE1SXPTECN0022234203AMBU-BAXGNTMDX688301603301002432.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Andon Health is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%NVSTFIE1SXP603014TECNAXGNTMDXICUI603301300003002432.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Andon Health is the large dot.

Andon Health competitors and peer comparison

Head to head with its named competitors (002432.SZ vs 300298.SZ vs 6645.T vs ABT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Andon Health 002432.SZ$3.86B-24%-30%-26%16.1×-6.6%
Sinocare 300298.SZ$1.45B+4%+7%6%21.5×9.5%
Omron 6645.T$5.65B-18%-3%11%17.0×8.7%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%

How Andon Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Andon Health against its 20 peers (data as of 18 Nov 2026)
Measure002432.SZPeer medianRank in peer set
1-month return+7.1%+3.5%10th highest of 21
6-month return-23.5%+11.1%2nd lowest of 21
Distance from 52-week high-40.1%-21.4%3rd lowest of 21
Revenue growth (TTM)-29.8%+7.4%lowest of 21
Operating margin-26.0%12.6%3rd lowest of 20
Forward P/E16.1×22.8×4th cheapest of 19
Growth the price implies (Req g, 7 yrs)-6.6%11.3%least demanding of 17
Growth delivered (Del g)-7.4%+8.5%2nd lowest of 17
Hurdle (Req g minus delivered)+0.8 pp+1.3 pp8th least demanding of 17
ROIC minus cost of capital-5.7 pp-0.8 pp5th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%

Questions

Who are Andon Health's main competitors?
Named competitors: Sinocare (300298.SZ), Omron (6645.T), Abbott (BinaxNOW) (ABT). The cockpit's measured peer set (industry) also includes CareDx (CDNA), Envista (NVST), Fielmann (FIE.DE), SCHOTT Pharma AG & Co. KGaA (1SXP.DE), Shandong Weigao Blood Purification Products (603014.SS), Tecan (TECN.SW).
Is Andon Health expensive compared with its peers?
On forward p/e it trades at 16.1× against a peer median of 22.8×, 4th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Andon Health stock performed?
Over six months to 18 Nov 2026 the shares returned -23.5% against +11.1% for the median peer; over one year +43.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.